Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Imatinib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AV-101
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Incubator
Deal Size: $72.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 06, 2020
Details:
Funding will advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension (PAH). An oral version of imatinib showed significant efficacy in a phase 3 trial as a disease-modifying therapy for PAH.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ticagrelor,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Brilinta
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020
Details:
The Phase III THALES results shows that a combination of twice daily Brilinta (ticagrelor) and daily aspirin reduced the rate of stroke and death by 17% after 30 days compared to aspirin alone in patients with acute ischemic stroke or transient ischemic attack.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ticagrelor,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Brilinta
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
Phase III THALES trial showed aspirin plus BRILINTA 90mg used twice daily for 30 days, resulted in a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ticagrelor,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2020
Details:
BRILINTA reduced the risk of the composite of stroke and death after an acute ischemic stroke or transient ischemic attack.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dapagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2020
Details:
The sNDA was based on results from the landmark Phase III DAPA-HF trial, which showed FARXIGA reduced the incidence of the composite outcome of CV death or the worsening of HF versus placebo.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
